Abstract
Introduction
Type-2 diabetes mellitus (T2DM) is a progressivedisease which is characterized by theelevation of glycated haemoglobinlevel (HbA1c) and decline in beta cells function. When lifestyle modification fails to achieve adequate glycaemic control, oral hypoglycemic agents are introduced as a treatment approach. [1, 2] If metformin is not contraindicated and can be tolerated, it should be considered as the firstline therapy in newly diagnosed T2DM patients with HbA1cless than 9%. [3] This is attributed to the advantages of weight loss, good initial efficacy in decreasing fasting plasma glucose in overweight and obese individuals with T2DM, and low cost [4] .
Gastrointestinal disturbance is a well-known side effect of metformin.It also can cause vitamin B 12 deficiency by reducing its absorption.
The increased frequency of vitamin B 12 deficiency among T2DMpatients had been reported in several cross sectional studies [6] [7] [8] and case reports [9] [10] [11] . The prevalence of vitamin B 12 deficiency ranged from 5.8% to 33% [6, 12, 13] .
Metformin induced vitamin B 12 deficiency is almost always overlooked and rarely taken into consideration [9, 14] . Many patients on metformin develop vitamin B 12 deficiency, consequently developing neuropathy and anaemia which is falsely attributed to underlying Diabetes mellitus by physicians and so never addressed [5] .
Furthermore, metformin, by decreasing vitamin B 12 levels, can increase plasma homocysteine level which is strongly linked to cardiovascular disease in patients with T2DM [15] .
Hence, the study was designed to evaluate the prevalence of metformin induced vitamin B 12 deficiency and the consequent elevation in homocysteine levels in type 2 diabetic Egyptian patients and whether the deficiency prevalence will be reduced by vitamin B 12 supplementation. 4. Information related to the duration of diabetes was obtained by questioning the patients.
Patients with adiagnosis of pernicious anaemia, malabsorption (coeliac disease, inflammatory bowel disease, gastrointestinal surgery), malnutrition (pure vegans, anorexia nervosa), iron deficiency anaemia, history of thyroid disease and thyroxine treatment and/or a history of other organ-specific autoimmune conditions (vitiligo, Addison's, primary ovarian failure, hypoparathyroidism) were excluded from the study.
Statistical analysis
All analysis of data was conducted through the use of IBM software SPSS 10.0 (SPSS Inc., Chicago, USA). The result of power analysis of the study for vitamin B 12 showed that sample size of 30 patients for each group is sufficient to get power of >80% and α=0.05. The two ways ANOVA analysis followed by post hoc ANOVA using Tukey system were used to analyse the difference in vitamin B 12 and homocysteine levels between groups. Correlation was assessed using Pearson (for normal distribution, linear correlation) and Spearman (for non-normal, non-linear correlation) tests as specified. All tests were two-sided and p-values of <0.05 were considered to be statistically significant. Post hoc assessment of multiple interactions was conducted by Tukey as indicated.
Results
A total of 88 (65 female) T2DM, with mean±SD (range) age 49.8±11.3 (22-75) years old were screened in the study. 30, 30 and 28 patients were in GP1, GP2 and GP3, respectively.
Patients' demographic and clinical characteristics are shown in Table 1 . No significant difference between the three groups was found in age, gender distribution, duration of DM, peripheral neuropathy and macrovascular complications. The mean±SD laboratory results of the three groups are shown in There was a statistically significant negative correlation between vitamin B 12 and homocysteine (r= -.448; p<0.001) as shown in Figure 1 . close to the prevalence of vitamin B12 deficiency shown in previous studies, which ranged from 5.8 to 30% in patients taking metformin [6, 12, 16, [18] [19] [20] .
This wide variation in the reported prevalence could probably be explained by the variability of measurement methods of vitamin B 12 levels in thelaboratories (HPLC, radio assay etc.) and difference in definitions of vitamin B 12 deficiency.
There is no definite mechanism of metformin-induced vitamin B 12 deficiency. Several hypotheses are available; include bacterial overgrowth in the small intestine, changes in small bowel motility, changes in bacterial flora, competitive inhibition or inactivation of vitamin B 12 absorption or an effect of calcium on cell membranes [15, 21, 23] .
The effect of metformin in decreasing plasma vitamin B 12 levels appears to be dependent on treatment duration and dose [22] [23] [24] of metformin and considered as a high risk factor for vitamin B 12 deficiency.
Several previous studies reported that metformin has no effect on homocysteine or small effect, if any [4, [25] [26] [27] . However, patients using metformin without vitamin B 12 supplementation in the present study showed high prevalence of vitamin B 12 deficiency. They had a relatively higher homocysteine level than that of patients using vitamin B 12
supplementation. However the difference within the three groups was not statistically significant that might be due to the number of patients studied. So, the decrease in vitamin B 12 concentrations was associated with an increase in homocysteine levels [22] . It was clearly shown that homocysteine concentrations increased with decreasing levels of vitamin B 12 and the correlation between them was negative and statistically significant (r =-0.448, p<0.01). nerve conduction tests are used to confirm diagnosis of peripheral neuropathy [28] . But, they
are not routinely performed at the outpatient level.
Anaemia was found to be prevalent in all groups of patients. However the prevalence was higher in vitamin B 12 deficient metformin group 55% than in patients with normal serum vitamin B 12 levels 37.5%, compared to 32% in the control group. The high incidence of anaemia in patients with T2DM is common and this may be due to the association of T2DM
with shortened red blood cell lifespan or possibly mild renal impairment. This was confirmed in our study as vitamin B 12 correlation with Hb and HCT was statistically significant [16] .
There were no significant differences in the mean MCV between with and without vitamin B 12 deficiency groups.
With regard to HC, as an important risk factor in vascular diseases in patients with diabetes, its levels were significantly higher in diabetic patients with cardiovascular diseases (CVD) than in normal subjects [29, 30] . We found significant correlation between homocysteine levels and macrovascular complications (e.g. hypertension, angina, and stroke) in diabetic patients (r=0.33, p<0.01). These results cannot confirm the relation between homocysteine and CVD complications because the difference in levels between groups was too small and non-significant. Also several factors are implicated in cardiovascular complications in diabetic patients.
Some population-based studies show little or no association between high homocysteine levels and CVD risk [31] . Hence, a causal role for homocysteine in the development of CVD is still debated. Vitamin B 12 deficiency also resulted in elevation in homocysteine levels; however the effect is seems to be small and insignificant.
